Thus, we sought to investigate whether the combination of DSP-0509, an AXL inhibitor, and TLR7 agonist induces robust activation of myeloid cells, resulting in a potent anti-tumor response within the tumor microenvironment. Here, TLR7 is linked to neoplasm.